Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer
- 1 December 2010
- journal article
- review article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 9 (5), 274-281
- https://doi.org/10.3816/ccc.2010.n.040
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Genetic prognostic and predictive markers in colorectal cancerNature Reviews Cancer, 2009
- PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2009
- Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFRCancer Treatment Reviews, 2009
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerThe New England Journal of Medicine, 2009
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal CancerJournal of Clinical Oncology, 2009
- Using Predictive Biomarkers to Select Patients With Advanced Colorectal Cancer for Treatment With Epidermal Growth Factor Receptor AntibodiesJournal of Clinical Oncology, 2008
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerThe New England Journal of Medicine, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- The use of molecular markers in the diagnosis and treatment of colorectal cancerBest Practice & Research Clinical Gastroenterology, 2007
- Cetuximab for the Treatment of Colorectal CancerThe New England Journal of Medicine, 2007